Arndt Vogel, MD

Articles

Other Frontline Immunotherapy-based Combinations in Advanced HCC

March 6th 2023

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Selecting the Appropriate Frontline Treatment in Advanced HCC

March 6th 2023

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

February 20th 2023

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

February 20th 2023

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Patients With Intermediate Stage HCC Suitable for TACE

February 20th 2023

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Patients With Intermediate Stage HCC Unsuitable for TACE

February 20th 2023

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Management of Hepatocellular Carcinoma: Future Directions in Care

November 11th 2022

Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

November 11th 2022

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Treatment Options for Advanced HCC in the Second-Line and Beyond

November 4th 2022

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

Novel First-Line Immunotherapy Approaches in Advanced HCC

November 4th 2022

Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.

Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

October 28th 2022

In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.

Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

October 28th 2022

Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.

Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

October 21st 2022

Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.

Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

October 21st 2022

Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.

Selecting the Appropriate First-Line Therapy for Advanced HCC

October 14th 2022

In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.

Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

October 14th 2022

Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.

Advanced HCC: Updates in First-line Systemic Therapy

October 7th 2022

Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.

Role of Systemic Therapy in Early- or Intermediate-Stage HCC

October 7th 2022

Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

Early- and Intermediate-Stage HCC Treatment Landscape

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.